Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taiwan Liposome Co. Ltd.

www.tlcbio.com

Latest From Taiwan Liposome Co. Ltd.

Asia Deal Watch: Oxford Biomedica’s First Japanese Partnership Focuses On Rare Retinal Disorder

Oxford Biomedica is teaming with Santen to develop a gene therapy for an undisclosed eye disease. Shionogi inks a pair of partnerships for Chinese rights to lusutrombopag and epertinib.

Deals Asia Pacific

Asia Executives On The Move: Comings And Goings At BeiGene, Harbour BioMed, TLC, GC Pharma

New Year brings a flurry of new executive moves in the life sciences sector in Asia Pacific, including the departure of BeiGene's chief commercial officer and a new chief strategy officer and CMO at Harbour Biomed.

Appointments Asia Pacific

Finance Watch: Alphamab's $100m Series A Continues Theme Of Big Investments In China Biopharma

The Suzhou-based drug developer brings in new cash as US venture deals take a holiday. Also, France's Genfit may go public in the US, Taiwan Liposome launches its IPO, and Bioblast's strategic review ends in a reverse merger.

Financing StartUps and SMEs

Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets

Not every drug developer can go public, but biopharma IPOs are launching in multiple markets, including Moderna's prospective $500m US offering and Innovent's $421m Hong Kong IPO. Also, Sarepta prices a $500m FOPO and Omeros sells $210m in notes.

Financing Asia Pacific
See All

Company Information

  • Industry
  • Biotechnology
    • Liposomes
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
  • Therapeutic Areas
  • Cancer
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Taiwan
  • Parent & Subsidiaries
  • Taiwan Liposome Co. Ltd.
  • Senior Management
  • Keelung Hong, Chmn. & CEO
    George Yeh, Pres.
    Yunlong Tseng, PhD, Dir., Research Dev.
    Cleo Pan, PhD, Dir., Preclinical
  • Contact Info
  • Taiwan Liposome Co. Ltd.
    Phone: 2 2655 7377
    11-F, 3 Yuang St.
    Nangang Dist.
    Taipei City, 11503
    Taiwan
Advertisement
Advertisement
UsernamePublicRestriction

Register